| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
TVTX
Travere Therapeutics
|
Aug 07, 2025 | BUY |
Strong Buy
-14.7% avg upside
22 analysts
|
$31.00
42.74% Downside
|
+207.8% |
|
EYPT
EyePoint Pharmaceuticals
|
Aug 07, 2025 | BUY |
Strong Buy
+129.0% avg upside
17 analysts
|
$18.00
34.12% Upside
|
+28.4% |
|
GERN
Geron
|
Aug 07, 2025 | HOLD |
Strong Buy
+241.8% avg upside
19 analysts
|
$1.50
17.73% Upside
|
+10.0% |
|
BBIO
BridgeBio Pharma
|
Aug 06, 2025 | BUY |
Strong Buy
+36.6% avg upside
34 analysts
|
$57.00
13.98% Downside
|
+50.4% |
|
OCUL
Ocular Therapeutix
|
Aug 06, 2025 | BUY |
Strong Buy
+153.7% avg upside
21 analysts
|
$20.00
111.82% Upside
|
-28.1% |
|
VRTX
Vertex Pharmaceuticals
|
Aug 05, 2025 | HOLD |
Strong Buy
-3.9% avg upside
61 analysts
|
$438.00
3.05% Downside
|
+22.4% |
|
AGIO
Agios Pharma
|
Aug 05, 2025 | BUY |
Strong Buy
+78.4% avg upside
29 analysts
|
$65.00
92.69% Upside
|
-22.2% |
|
ALNY
Alnylam Pharma
|
Aug 01, 2025 | BUY |
Strong Buy
+22.4% avg upside
51 analysts
|
$450.00
63.86% Upside
|
-29.6% |
|
RCKT
Rocket Pharmaceuticals
|
Jul 25, 2025 | BUY |
Buy
+418.9% avg upside
29 analysts
|
$19.00
491.85% Upside
|
-5.7% |
|
GOSS
Gossamer Bio
|
Jul 14, 2025 | BUY |
Buy
+4259.1% avg upside
17 analysts
|
$11.00
6467.23% Upside
|
-77.8% |
|
ARCT
Arcturus Therapeutics
|
Jul 02, 2025 | BUY |
Buy
+298.1% avg upside
35 analysts
|
$35.00
375.45% Upside
|
-38.3% |
|
IRON
Disc Medicine
|
Jun 17, 2025 | BUY |
Strong Buy
+21.2% avg upside
21 analysts
|
$75.00
6.72% Upside
|
+40.0% |
|
LQDA
Liquidia Technologies
|
Jun 11, 2025 | BUY |
Strong Buy
-26.3% avg upside
15 analysts
|
$37.00
46.28% Downside
|
+406.9% |
|
KROS
Keros Therapeutics
|
Jun 10, 2025 | BUY |
Strong Buy
+143.6% avg upside
21 analysts
|
$26.00
148.32% Upside
|
-23.6% |
|
VERA
Vera Therapeutics
|
Jun 02, 2025 | BUY |
Strong Buy
+90.9% avg upside
19 analysts
|
$65.00
86.35% Upside
|
-1.5% |
|
BEAM
Beam Therapeutics
|
Apr 07, 2025 | BUY |
Strong Buy
+57.5% avg upside
25 analysts
|
$40.00
21.44% Upside
|
+60.1% |
|
EDIT
Editas Medicine
|
Aug 08, 2024 | BUY |
Buy
+434.5% avg upside
33 analysts
|
$15.00
482.53% Upside
|
-47.4% |
|
NTLA
Intellia Therapeutics
|
Jun 03, 2024 | BUY |
Buy
+158.2% avg upside
37 analysts
|
$80.00
424.41% Upside
|
-67.3% |
|
MLYS
Mineralys Therapeutics, Inc.
|
Mar 21, 2024 | BUY |
Strong Buy
+78.6% avg upside
12 analysts
|
$36.00
41.61% Upside
|
+28.9% |
|
BTAI
Bioxcel Therapeutics
|
Mar 12, 2024 | BUY |
Buy
+1935.1% avg upside
12 analysts
|
$112.00
9351.46% Upside
|
-94.5% |
|
ALEC
Alector
|
Feb 27, 2024 | HOLD |
Hold
+606.7% avg upside
14 analysts
|
$9.00
460.69% Upside
|
-76.3% |
|
TYRA
Tyra Bioscience
|
Dec 22, 2023 | HOLD |
Strong Buy
+55.7% avg upside
17 analysts
|
$15.00
46.85% Downside
|
+38.8% |
|
OMER
Omeros
|
Oct 16, 2023 | SELL |
Buy
+113.6% avg upside
14 analysts
|
$0.50
95.06% Downside
|
-168.8% |
|
PMVP
PMV Pharmaceuticals
|
Oct 11, 2023 | BUY |
Strong Buy
+1237.5% avg upside
12 analysts
|
$17.00
1459.61% Upside
|
-68.6% |
|
SGMO
Sangamo Therapeutics
|
Oct 10, 2023 | HOLD |
Buy
+5737.2% avg upside
16 analysts
|
— | +50.9% |
|
STOK
Stoke Therapeutics
|
Oct 10, 2023 | HOLD |
Strong Buy
+28.2% avg upside
18 analysts
|
— | +178.1% |
|
UTHR
United Therapeutics
|
Sep 29, 2023 | SELL |
Buy
-20.4% avg upside
26 analysts
|
$177.00
67.11% Downside
|
-58.7% |
|
NKTR
Nektar Therapeutics
|
Sep 13, 2023 | SELL |
Buy
+18.4% avg upside
25 analysts
|
$0.60
98.93% Downside
|
-89.9% |
|
SNTI
Senti Biosciences
|
Feb 06, 2023 | BUY |
Strong Buy
+820.3% avg upside
7 analysts
|
$6.00
531.24% Upside
|
-74.5% |
|
LENZ
LENZ Therapeutics
|
Feb 06, 2023 | HOLD |
Buy
+280.4% avg upside
17 analysts
|
$3.00
49.07% Downside
|
+26.7% |
|
NGNE
Neurogene
|
Sep 12, 2022 | SELL |
Buy
+58.4% avg upside
23 analysts
|
$1.00
96.83% Downside
|
+31.8% |
|
ATHXQ
Athersys
|
May 23, 2022 | SELL |
Buy
+29964185.8% avg upside
8 analysts
|
$6.25
6249900.08% Upside
|
+81.9% |
|
S
SentinelOne
|
Mar 16, 2022 | BUY |
Strong Buy
+67.4% avg upside
63 analysts
|
$54.00
268.34% Upside
|
-56.6% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.